Millipore Announces Technology Acquisition to Strengthen Drug Discovery Product Offering
News Mar 02, 2009
Millipore has announced that it has purchased the assets associated with Epitome Biosystems’ EpiTag™ technology. The purchase price was not disclosed.
The technology acquisition will enable Millipore’s Bioscience Division to expand its presence in the fast growing multiplex immunoassay market by offering scientists a broader portfolio of cell signaling assays that can be used with the Luminex xMAP® platform. Additionally, the acquisition will allow for the future development of other novel profiling technologies.
“Our multiplex offering is one of our fastest growing product lines and the acquisition of the EpiTag technology will help us to accelerate our product development and expand our growth prospects in this dynamic market,” said Rick Ryan, Vice President of Millipore’s Drug Discovery Business Unit.
”Our customers are interested in better understanding the roles that cell pathways play in major diseases such as cancer and diabetes. The EpiTag technology will allow us to develop multiplex immunoassays for cellular targets that were previously very difficult to detect and quantify. As a result, we will enable customers to leverage the power of the Luminex xMAP platform for cell signaling by providing antibodies and kits that are specific to the highest areas of interest for researchers,” Ryan said.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019